← All trials
NCT04934670
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- Jan 1, 2025
- Completion date
- Jan 1, 2026
- First posted
- Jun 22, 2021
- Last posted
- Dec 2, 2021
- Enrollment
- 246
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- XenikosLead sponsor
- Center for International Blood and Marrow Transplant ResearchStudy director
- National Cancer Institute (NCI)Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Marrow Donor ProgramCollaborator
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
- XenikosStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.